Fate Therapeutics (NASDAQ: FATE)
Key Data Points
Fate Therapeutics Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Fate Therapeutics Company Info
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
News & Analysis
3 Cathie Wood Stocks for the Future
Unlike a lot of tech investors, Cathie Wood is super bullish on biotechnology. Here are three of her picks that these Motley Fool contributors love.
Cathie Wood Likes Fate Therapeutics, Should You?
The biotech has an interesting pipeline, but it's all early stage products.
3 Biotech Stocks That Can Double Your Money, According to Wall Street
All three of these stocks could rise over 100% once stock-market sentiment falls in line with the opinions of investment-bank analysts.
Recent Poor Results Have Made This Promising Cathie Wood Pick a Bargain
Positive news versus poor clinical trial results may determine the future of Fate Therapeutics.
Why Fate Therapeutics Stock Is Sliding Today
The positive results the company announced after the bell yesterday didn't meet some lofty expectations.
Did You See What Cathie Wood Bought on Wednesday?
ARK Invest added to its stakes in DraftKings, Fate Therapeutics, and Zoom Video, all of which are trading well below their recent peaks.
3 of the Most Innovative Stocks to Buy Now
Here's how shares a diversified e-commerce firm, an immunotherapy biotech, and an electronic agreement company can make you rich.
2 Under-the-Radar Stocks Cathie Wood Loves That Could Be Huge Winners
These biotech companies are small, but they have tremendous growth prospects.
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.